Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017168 (gastroesophageal reflux disease)
 11,783 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Proton pomp inhibitors (PPI) have revolutionized the treatment of gastro-oesophageal reflux disease and gastro-duodenal ulcers. Rabeprazole (Pariet) is the last PPI arrived on the Belgian market. Controlled studies have shown an efficacy similar to emeprazole in the treatment of oeso-gastro-duodenal acid diseases. Rabeprazole has a favourable profile with rapid action and good safety.
 ...
PMID:[Pharma-clinics medication of the month. Rabeprazole (Pariet)]. 1189

The article provides the data on 20 patients with erosive reflux esophagitis, who were treated with Pariet (rabeprazole). It was shown on the basis of conducted clinical endoscopic, morphological and immunohistochemical studies that the application of Pariet in treatment of patients with erosive esophagitis contributes to clinical endoscopic remission, regression of inflammatory changes, recovery of apoptosis processes and proliferative activity of esophagus epithelial cells within a shorter period of time. The results of the observation allow recommending Pariet as a highly efficient preparation for treatment of patients with gastroesophageal reflux disease.
 ...
PMID:[Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis]. 1250 69

This clinical endoscopic study is of interest because clinical and endoscopic remission of the disease with a torpid course was achieved in a patient with gastroesophageal reflux disease with a continuously recurrent course complicated with leukoplakia under the condition of regular combination of preparations of the base course PPIs (Pariet) + prokinetic agent (Motilium) + antacid (Magalphil), conduction of continuous treatment during 12 weeks and subsequent supporting therapy (Pariet, 20 mg) during 6 months in the weekend treatment mode, as well as adherence to recommendations for changing the lifestyle.
 ...
PMID:[A case of the successful treatment of the esophageal leukoplakia with rabeprazole]. 1250 73

The research was aimed at evaluating the efficiency of the inhibitor of the Rabeprazole (Pariet) proton pump in the therapy of the gastroesophageal reflux disease (GERD) with extra esophagus manifestations, and the presence of pains in the chest not caused by cardiac diseases. 37 patients suffering from GERD underwent monotherapy with inhibitors of the proton pump: 17 patients were taking Omeprazole 40 mg a day, and 20 patients--Rabeprazole 20 mg a day. The treatment with Rabeprazole supplied authentic data concerning faster pain reduction in the heart area and heartburn starting from the first day of treatment. According to the daily pH monitoring, administration of Pariet is accompanied by a reliably much more manifested reduction of the total time with pH less than 4 in the esophagus as compared to Omeprazole. The data received demonstrate the advantages of using Pariet in the treatment of GERD with atypical symptoms.
 ...
PMID:[Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease]. 1462 3

At present proton pump inhibitors have been the most efficient drugs for treating the gastroesophageal reflux disease (GERD). Pariet may be selected as a drug for treating all forms of GERD as it requires smaller doses and shorter treatment period to obtain the clinical and endoscopic remission. Upon the clinical and endoscopic remission, patients need a supportive treatment. Different patients need various supportive treatment schemes. Our goal comes to the provision of the maximum efficiency of the schemes when prescribing the minimum doses of the drug.
 ...
PMID:[Some comparative aspects of treating the gastroesophageal reflux disease eradication]. 1556 Apr 1

There is growing recognition of the importance of assessing patient perceptions of treatment, especially patient satisfaction. The Gastroesophageal Reflux Disease (GERD) Treatment Satisfaction Questionnaire (GTSQ) was developed to assess satisfaction with GERD medication. A web-based survey, which included the GTSQ and the GERD Symptom Assessment Scale (GSAS), was administered in September 2003 to 2511 subjects taking prescription GERD medication, identified as H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). Results showed excellent reliability of the GTSQ subscales (from 0.82-0.95) and validity with respect to two GSAS subscales. Rabeprazole (Aciphex) subjects taking 1 pill per day were statistically more satisfied than those taking 2 pills per day for all subscales except "Daytime Relief" and "Quick and Long-Lasting." Those who stayed on rabeprazole therapy longer showed statistically significant greater satisfaction on the "Daytime Relief" and "Health-Related Quality of Life" scales. The GTSQ has high reliability and can be used to assess aspects of satisfaction with GERD medication.
 ...
PMID:Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire. 1624 Feb 10

Rabeprazole is among the most potent proton pump inhibitors (PPI) identified to date and it has been demonstrated that it is effective in such diseases as gastroesophageal reflux disease (GERD), duodenal ulcer and gastric ulcer. There is currently interest in developing a new formulation: rabeprazole sterile powder for injection (RSPI). This investigation was conducted to evaluate the preclinical pharmacokinetics of RSPI in rats and at the same time a comparative study was carried out in dogs between RSPI and Pariet tablets using liquid chromatographic-mass spectrometry analysis. The liquid chromatographic-mass spectrometry method was first conducted and validated as being specific, and having accuracy, precision, sensitivity and a satisfactory recovery. After intravenous administration of RSPI (i.v.: 2, 6 and 18 mg/kg) to rats, no significant dose-dependency was found in the CL (4.20-5.72 l/h/kg), V(area) (d) (0.94-1.32 l/kg), dose-normalized AUC (197.20-245.82 microg/l*h based on 1 mg/kg) and t(1/2) (p>0.05). In the dog, a randomized, open-label, crossover experiment was carried out to show that the mean area under the plasma concentration-time curve (AUC(0-infinity)) after i.v. administration of RSPI was at least four times larger than that following oral administration of Pariet tablet at an equivalent dose but the elimination half-life of these two formulation was similar (p>0.05). The results showed that the pharmacokinetics of RSPI was linear (r(2) = 0.98) in the dose range 2-18 mg/kg and the RSPI had a much higher AUC(0-infinity) and similar t(1/2) values compared with the enteric-coated tablet.
 ...
PMID:Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. 1737 59

Rabeprazole (Aciphex, Alfence, Pariet) is a proton pump inhibitor (PPI) used for the treatment of adults with conditions requiring a reduction of gastric acid secretion such as erosive or ulcerative gastro-oesophageal reflux disease (GORD), non-erosive reflux disease (NERD), duodenal and gastric ulcers, and pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES). It is also used as part of combination therapy for the eradication of Helicobacter pylori, a pathogen frequently implicated in the development of gastric and duodenal ulcers. Rabeprazole has a well established efficacy and safety profile in the treatment of gastric acid-related diseases. Rabeprazole is a useful, well tolerated and cost-effective option for the treatment of GORD, NERD, peptic ulcer and other gastric acid-related diseases (including ZES), and provides an appropriate alternative to other currently available PPIs, with the added benefits of having a consistent efficacy profile and low drug interaction potential due to its predominantly nonenzymatic metabolism.
 ...
PMID:Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. 1958 55